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on the results. The trial included 609 patients. Of these, 402 received PDT with verteporfin and 207 received placebo. There were no reports of patients refusing to participate, or patients excluded for any reason.
Study design
The analysis was based on a randomised placebo-controlled trial, in which one eye from each patient was randomised. The patients were followed for 2 years at 3-monthly follow-up visits. It was unclear whether the study was carried out in a single centre or multiple centres. There was no reported loss to follow-up. There was no reported blinding of the outcome assessment.
Analysis of effectiveness
The analysis seems to have been conducted on an intention to treat basis, although this was not stated explicitly. The primary health outcome was moderate vision loss, which was defined as the loss of less than three lines of VA (15 letters). The authors did not report the comparability of the patient groups at analysis, although this information might have been reported in the primary source.
Effectiveness results
Of those patients treated with verteporfin, 53% lost less than three lines of vision compared with 38% of placebotreated eyes, (p<0.001).
For patients treated with verteporfin, 82% did not experience severe vision loss (defined as more than six lines, or less than 30 letters) compared with 70% of placebo-treated eyes, (p<0.001).
In patients with minimally classic lesions, PDT and placebo groups had similar visual outcomes (48% for verteporfin patients versus 44% of the placebo patients). However, patients with predominantly classic lesions who were given PDT had lower vision loss (59% of those verteporfin versus 31% of those on placebo). The statistical analysis was not reported.
Clinical conclusions
Clinical conclusions were not explicitly drawn as the results were presented in a parent study. Since the UK recommendations indicate that only patients with predominantly classic CNV should be treated with verteporfin, the analysis focused on the sub-set of 243 patients with that particular form of disease.
Modelling
A Markov model was used to combine the effectiveness data with the costing data over 2-and 5-year time horizons. The model incorporated health states ranging from visual acuity of 20/40 to worse than 20/800, plus the dead state. A survival analysis using a Weibull function was used to estimate daily transition probabilities, controlling for baseline VA, gender and age.
Methods used to derive estimates of effectiveness
Authors' assumptions were used to supplement the effectiveness evidence for the model.
Estimates of effectiveness and key assumptions
The authors made the following assumptions.
There were 1.52 re-treatments per person from year 2 to year 3 and none thereafter, and re-treatment was independent of baseline visual acuity.
Once follow-up was completed, there would be no further follow-up visits for those patients in the PDT treatment arm. The better seeing eye would normally be treated.
Approximately 92% of the patients eligible for PDT with verteporfin would not have been eligible for treatment with laser photocoagulation.
There was no allowance for improvement in vision associated with verteporfin treatment, only slowed deterioration.
Measure of benefits used in the economic analysis
The 
Direct costs
The costing was carried out from the perspectives of the National Health Service (NHS; treatment costs only) and the government (incorporating cost offsets). The estimate of treatment costs only included the cost of verteporfin and disposables, laser, angiography, outpatient appointment and adverse events. Other costs associated with the government perspective included possible cost offsets in medical and social care (such as blindness registration, low vision aids, rehabilitation services, housing and council tax benefit, depression treatment, hip replacement community care and residential care). The estimates were taken from NICE's technology assessment report on PDT with verteporfin that was published in 2002. This report incorporated information from a range of sources. More specifically, published national sources (the British National Formulary; NHS Reference Costs; Personal Social Services Research Unit Costs of Health and Social Care), primary literature and some primary data collection. The costs were discounted at a rate of 6%. All the costs were inflated to December 2000 prices. The analysis separated the categories of cost, but the unit costs were not reported separately from the quantities.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
The indirect costs were not estimated, which was appropriate given the perspective adopted.
Currency
UK pounds sterling ().
Sensitivity analysis
One-way sensitivity analyses were carried out using the lower limit of the range of cost offsets and the low estimate for angiography follow-up. Cost-effectiveness acceptability curves were generated, varying transition probabilities and health state utilities, to assess the probability of verteporfin being cost-effective for different values of willingness-topay for health outcomes.
Estimated benefits used in the economic analysis
The results presented are those from the broader perspective of the government.
Over a timeframe of 2 years with baseline VA of 20/40, the number of vision-years was 1.618 with placebo and 1.773 Over a timeframe of 2 years with baseline VA of 20/100, the number of vision-years was 1.074 with placebo and 1.383 with verteporfin (difference 0.309). The number of QALYs was 0.980 with placebo and 0.995 with verteporfin (difference 0.015).
Over a timeframe of 5 years with baseline VA of 20/40, the number of vision-years was 2.160 with placebo and 3.050 with verteporfin (difference 0.890). The number of QALYs was 2.205 with placebo and 2.375 with verteporfin (difference 0.170).
Over a timeframe of 5 years with baseline VA of 20/100, the number of vision-years was 1.222 with placebo and 1.858 with verteporfin (difference 0.636). The number of QALYs was 1.999 with placebo and 2.093 with verteporfin (difference 0.094).
Cost results
Over a timeframe of 2 years with baseline VA of 20/40, the cost of treatment was 1,275 with placebo and 6,490 with verteporfin (difference 5,215).
Over a timeframe of 2 years with baseline VA of 20/100, the cost of treatment was 4,590 with placebo and 8,878 with verteporfin (difference 4,288).
Over a timeframe of 5 years with baseline VA of 20/40, the cost of treatment was 10,200 with placebo and 11,700 with verteporfin (difference 1,500).
Over a timeframe of 5 years with baseline VA of 20/100, the cost of treatment was 15,700 with placebo and 18,500 with verteporfin (difference 2,800).
Synthesis of costs and benefits
Over a 2-year horizon with VA of 20/40, the cost per vision-year gained was 33,645 with verteporfin and the cost per QALY gained was 75,580.
Over a 2-year horizon with VA of 20/100, the cost per vision-year gained was 13,877 with verteporfin and the cost per QALY gained was 285,867.
Over a 5-year horizon with VA of 20/40, the cost per vision-year gained was 1,685 with verteporfin and the cost per QALY gained was 8,823.
Over a 5-year horizon with VA of 20/100, the cost per vision-year gained was 4,402 with verteporfin and the cost per QALY gained was 29,787.
